Pursuing T-Cell Targeting for the Next Frontier in Autoimmune Remission

• Discussing why B-cell targeted therapies alone is often insufficient
• Emphasizing the need to break the T/B-cell axis to modulate T-helper cells that provide survival and differentiation signals for pathogenic B-cells
• Defining the necessary therapeutic precision, selective manipulation or depletion of pathogenic T-cell subsets while preserving the protective, conventional T-cell immunity

Speakers:

Zhen Su

Chief Executive Officer

Marengo Therapeutics